GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Henlius Biotech 2696.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

49.78

+1.55%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About Shanghai Henlius Biotech

Its shares trade on HKEX under the ticker 2696.HK. It has been listed since 25 September 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥7.78bn and net income of CN¥939.8m. At that date it held total assets of CN¥14.43bn and shareholders' equity of CN¥4.62bn.

Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Sept 2019
Employees
1,172
Website
henlius.com ↗

Leadership

Pay as last reported

  • Mr. Wenjie ZhangExecutive Chairman of the Board, since 2019CN¥28.0m
  • Ms. Wei HuangPresident, Chief Operating Officer, Senior Vice President
  • Mr. Jun ZhuChief Executive Officer, Executive Director, since 2021
  • Mr. Yingbo MaoChief Financial Officer, Vice President
  • Mr. Xinjun GuoSenior Vice President
  • Ms. Ping CaoVice President
  • Mr. Cheng YuVice President, Chief Business Officer
  • Ms. Wan Kai ChongJoint Company Secretary
  • Ms. Ching Ching LeungJoint Company Secretary
  • Ms. Yan WangJoint Company Secretary
  • Mr. Zhang WenjieJoint Company Secretary
  • Mr. Qiyu ChenNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shanghai Henlius Biotech Inc has a strong portfolio of innovative biotech products, allowing them to compete effectively in the market.
  • The company has a talented and experienced team of scientists and researchers who drive the development of high-quality, effective drugs.
  • Shanghai Henlius Biotech Inc has established strong partnerships with reputable pharmaceutical companies, enabling them to leverage their resources and expand their market reach.
  • The company has a robust manufacturing infrastructure and distribution network, ensuring efficient production and timely delivery of their products.
  • Shanghai Henlius Biotech Inc has a solid financial position, allowing them to invest in research and development and further enhance their product pipeline.
  • Although Shanghai Henlius Biotech Inc has a strong portfolio, they face the challenge of intense competition in the biotech industry.
  • The company may rely heavily on a few key products, making them vulnerable to fluctuations in demand and market dynamics.
  • Shanghai Henlius Biotech Inc may have limited market presence in certain regions, restricting their revenue potential.
  • The company's research and development process may be lengthy and costly, impacting their ability to quickly bring new products to market.
  • Shanghai Henlius Biotech Inc may lack the same brand recognition and reputation as some of their larger competitors.
  • The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.
  • Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.
  • Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.
  • The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.
  • Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.
  • The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.
  • Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.
  • The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.
  • Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.
  • Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Weaknesses

  • Although Shanghai Henlius Biotech Inc has a strong portfolio, they face the challenge of intense competition in the biotech industry.
  • The company may rely heavily on a few key products, making them vulnerable to fluctuations in demand and market dynamics.
  • Shanghai Henlius Biotech Inc may have limited market presence in certain regions, restricting their revenue potential.
  • The company's research and development process may be lengthy and costly, impacting their ability to quickly bring new products to market.
  • Shanghai Henlius Biotech Inc may lack the same brand recognition and reputation as some of their larger competitors.
  • The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.
  • Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.
  • Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.
  • The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.
  • Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.
  • The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.
  • Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.
  • The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.
  • Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.
  • Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Opportunities

  • The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.
  • Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.
  • Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.
  • The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.
  • Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.
  • The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.
  • Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.
  • The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.
  • Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.
  • Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Threats

  • The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.
  • Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.
  • The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.
  • Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.
  • Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.